IO BIOTECH INC. - COM

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

08 Aug 2023 08:05:00 By Nasdaq GlobeNewswire

IO Biotech, Inc. Announces $75 Million Private Placement Financing

07 Aug 2023 08:30:12 By Nasdaq GlobeNewswire

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

28 Jul 2023 08:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

25 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

18 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

14 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

01 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

IO Biotech to Present at the Jefferies Healthcare Conference

30 May 2023 16:35:00 By Nasdaq GlobeNewswire

IO Biotech Announces 2023 First-Quarter Results

11 May 2023 16:05:01 By Nasdaq GlobeNewswire

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

14 Mar 2023 16:11:47 By Nasdaq GlobeNewswire

IO Biotech to Participate in March 2023 Investor Conferences

22 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Appointment of Devin Smith as General Counsel

23 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

IO Biotech Provides Business Update

09 Jan 2023 07:05:46 By Nasdaq GlobeNewswire

IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

09 Nov 2022 16:08:30 By Nasdaq GlobeNewswire

IO Biotech Announces Third Quarter Results for 2022

09 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors

03 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

IO Biotech to Participate in the Jefferies London Healthcare Conference

31 Oct 2022 08:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Appointment of New Chief Financial Officer

13 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

05 Oct 2022 08:05:00 By Nasdaq GlobeNewswire

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

06 Sep 2022 07:30:00 By Nasdaq GlobeNewswire